Vitiligo and Stroke Risk
Patients with vitiligo have an increased risk of stroke and should be screened and managed for cardiovascular risk factors, though they do not require vitiligo-specific stroke prevention therapy beyond standard cardiovascular risk management.
Evidence for Increased Stroke Risk
The most recent high-quality evidence demonstrates that vitiligo is associated with elevated cardiovascular disease risk. A large-scale US retrospective study of 96,581 propensity-matched patients found that cerebral infarction occurred in 1.3% of vitiligo patients versus 1.0% of controls, with a hazard ratio of 1.21 (95% CI 1.11-1.32) 1. This same study showed venous thromboembolism rates of 1.34% in vitiligo patients versus 1.02% in controls (HR 1.27,95% CI 1.17-1.38), and an overall increased risk for major adverse cardiovascular events (MACE) with HR 1.28 (95% CI 1.22-1.35) 1.
Underlying Mechanisms
The increased stroke risk in vitiligo patients appears mediated through traditional cardiovascular risk factors that occur at higher rates in this population. Meta-analysis reveals that vitiligo patients have significantly elevated rates of:
- Hypertension: 15.8% comorbidity rate
- Hyperlipidemia: 43.0% comorbidity rate
- Diabetes: 6.0% comorbidity rate
- Metabolic syndrome: 28.3% comorbidity rate
- Obesity: 38.5% comorbidity rate 2
Additionally, vitiligo patients demonstrate significantly different metabolic parameters compared to controls, including elevated fasting blood glucose, insulin levels, systolic and diastolic blood pressure, total cholesterol, triglycerides, LDL, homocysteine, and C-reactive protein 2.
Clinical Management Approach
Screening Recommendations
All vitiligo patients should undergo cardiovascular risk factor screening, including:
- Blood pressure measurement
- Lipid panel (total cholesterol, LDL, HDL, triglycerides)
- Fasting glucose or HbA1c
- Assessment for metabolic syndrome components
- Thyroid function testing (given high prevalence of autoimmune thyroid disease in vitiligo) 3
Stroke Prevention Strategy
Apply standard primary stroke prevention guidelines rather than vitiligo-specific protocols. The 2024 AHA/ASA Primary Prevention of Stroke Guideline provides the framework 4:
Blood pressure management is critical - Most patients requiring pharmacological treatment need ≥2 antihypertensive medications to reach goal 4
Mediterranean diet supplemented with nuts and olive oil reduces stroke risk 4
Regular moderate-to-vigorous physical activity with avoidance of prolonged sedentary behavior 4
For patients with diabetes and high cardiovascular risk: Consider GLP-1 receptor agonists, which reduce cardiovascular disease and stroke risk 4
Address social determinants of health that may impact access to care and treatment adherence 4
Special Considerations
Antiplatelet therapy is NOT routinely indicated for vitiligo alone. The 2024 stroke prevention guideline recommends antiplatelet therapy specifically for antiphospholipid syndrome or systemic lupus erythematosus 4, but vitiligo itself does not warrant prophylactic antiplatelet use.
The increased stroke risk appears to be a consequence of the higher burden of traditional cardiovascular risk factors rather than a direct thrombotic effect of vitiligo itself. Therefore, aggressive management of modifiable risk factors (hypertension, diabetes, hyperlipidemia, obesity) represents the primary prevention strategy.
Important Caveats
- Most evidence comes from Eastern populations; extrapolation to Western populations requires caution 2
- The vitiligo guidelines from 2008 do not address cardiovascular screening, as this association was not well-established at that time [@2-11@]
- Regular monitoring is essential - patients with vitiligo should have ongoing cardiovascular risk assessment as part of routine care 1
- The absolute risk increase is modest but clinically meaningful given vitiligo's prevalence and the young age of onset (average 20 years) 3